Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663852 | 1.00 | ATM (0.53) | ATMEPHX1SMN1; SMN2KDM4EEPHX2 | |
| SCHEMBL19493238 | 1.00 | ATM (0.53) | ATMEPHX1SMN1; SMN2KDM4EEPHX2 | |
| SCHEMBL22546765 | 1.00 | ATM (0.53) | ATMEPHX1SMN1; SMN2KDM4EEPHX2 | |
| SCHEMBL24213834 | 1.00 | ATM (0.53) | ATMEPHX1SMN1; SMN2KDM4EEPHX2 | |
| SCHEMBL5220264 | 1.00 | ATM (0.53) | ATMEPHX1SMN1; SMN2KDM4EEPHX2 | |
| SCHEMBL24213833 | 1.00 | ATM (0.53) | ATMEPHX1SMN1; SMN2KDM4EEPHX2 | |
| SCHEMBL22546666 | 1.00 | ATM (0.53) | ATMEPHX1SMN1; SMN2KDM4EEPHX2 | |
| SCHEMBL24323695 | 1.00 | ATM (0.53) | ATMEPHX1SMN1; SMN2KDM4EEPHX2 | |
| SCHEMBL22546809 | 1.00 | ATM (0.53) | ATMEPHX1SMN1; SMN2KDM4EEPHX2 | |
| Hydrochloric Acid SCHEMBL5742263 | 0.98 | ATM (0.51) | ATMEPHX1SMN1; SMN2KDM4EEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101309690-A | Chemokine receptor binding compounds | ANORMED INC (CA) | 2008-11-19 | — | — | CN | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20060211740-A1 | Novel compounds | GLAXO GROUP LIMITED | 2006-09-21 | — | — | US | disclosed |
| CN-1735592-A | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LTD (GB) | 2006-02-15 | — | — | CN | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | ATM 870/4885EPHX1 383/4885SMN1; SMN2 478/4885 |
| US-20060211740-A1 | Novel compounds | BACE2, BACE1, PSEN2 | ATM 1026/4885EPHX1 1133/4885SMN1; SMN2 756/4885 |
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | ATM 3779/4885EPHX1 1750/4885SMN1; SMN2 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.